Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00937716 · ClinicalTrials.gov registry record
Treatment Response in Schizophrenia: Bridging Imaging and Postmortem Studies
A clinical trial, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 75
- Enrollment target
NCT00937716 is a clinical trial that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 75 participants.
The verdict
NCT00937716 has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 75 participants
- Enrollment target
Study Summary
The overarching goal is to identify imaging markers that will predict treatment response, and to confirm or validate these biomarkers using anatomical studies of postmortem tissue. Early detection of drug response would yield specific treatment strategies that are tailored to the individual, thus improving both the quality of life of the patients and drastically reducing the costs associated with unsuccessful treatment strategies.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2008-10 |
| Est. Completion | 2021-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00937716
The ClinicalTrials.gov registry entry for NCT00937716 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00937716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00937716 about?
NCT00937716 is a clinical study titled "Treatment Response in Schizophrenia: Bridging Imaging and Postmortem Studies". The overarching goal is to identify imaging markers that will predict treatment response, and to confirm or validate these biomarkers using anatomical studies of postmortem tissue. Early detection of drug response would yield specific treatment strategies that are tailored to the individual, thus im...
What is the current status of trial NCT00937716?
This trial is currently completed. The enrollment target is 75 participants. The study started on 2008-10. Estimated completion is 2021-06-30.
Who is sponsoring clinical trial NCT00937716?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.